CLL

The combination use of Imbruvica (ibrutinib) with Rituxan (rituximab) significantly improved survival outcomes compared with standard of care in younger patients with chronic lymphocytic leukemia (CLL).

Former NFL coach discusses how cancer motivated him to appreciate life.

Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).

Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.

In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.

Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.

Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.

An oncologist and three advocates were honored for their work on behalf of people with chronic lymphocytic leukemia.

While CAR-T cell therapy has potential in treating CLL, T-cell fatigue and toxicity still raise many concerns.

CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.

What’s the best plan for lowering cancer drug prices? A panel of experts debated the possibilities.

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

Chronic lymphocytic leukemia can now be managed as a long-term condition, and there are new ways loved ones can help.

The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.

Equipping with knowledge to improve patient-physician communication and understanding the disease.

An expert provides tips for maximizing time with your oncologist and adhering to oral medication.

Better treatment options have put chronic lymphocytic leukemia in the spotlight in recent years. But just what is CLL?

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.

A new drug combination bested current standard of care in a clinical trial.